How to buy Cara Therapeutics (CARA) shares in Australia
Learn how to easily invest in Cara Therapeutics shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cara Therapeutics Inc is a biotechnology business with stocks listed in the US. Cara Therapeutics shares (CARA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$11.95 – an increase of 2.58% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Cara Therapeutics
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Cara Therapeutics. Find the share by name or ticker symbol: CARA. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cara Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$11.65, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Cara Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Cara Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Cara Therapeutics key stats
- Compare share trading platforms
- Is Cara Therapeutics stock a buy or sell?
- Cara Therapeutics performance over time
- Are Cara Therapeutics shares over-valued?
- Cara Therapeutics's financials
- How volatile are Cara Therapeutics shares?
- Does Cara Therapeutics pay a dividend?
- Have Cara Therapeutics shares ever split?
- Other common questions
Cara Therapeutics stock price (NASDAQ:CARA)Use our graph to track the performance of CARA stocks over time.
Cara Therapeutics shares at a glance
|52-week range||US$11.22 - US$29.6473|
|50-day moving average||US$13.3134|
|200-day moving average||US$14.9628|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$0.479|
Where to buy Cara Therapeutics stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Cara Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Cara Therapeutics price performance over time
|1 week (2022-01-14)||11.95|
|1 month (2021-12-21)||-2.77%|
|3 months (2021-10-21)||-8.01%|
|6 months (2021-07-21)||-7.79%|
|1 year (2021-01-21)||-37.04%|
|2 years (2020-01-21)||-29.16%|
|3 years (2019-01-18)||-22.15%|
|5 years (2017-01-20)||4.55%|
Stocks similar to Cara Therapeutics
Is Cara Therapeutics under- or over-valued?
Valuing Cara Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cara Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cara Therapeutics's P/E ratio
Cara Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Cara Therapeutics shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Cara Therapeutics's EBITDA
Cara Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$23 million (£0.0 million).
The EBITDA is a measure of a Cara Therapeutics's overall financial performance and is widely used to measure a its profitability.
Cara Therapeutics financials
|Revenue TTM||US$134.3 million|
|Operating margin TTM||16.93%|
|Gross profit TTM||US$27.2 million|
|Return on assets TTM||7.63%|
|Return on equity TTM||14.24%|
|Market capitalisation||US$638.8 million|
TTM: trailing 12 months
Cara Therapeutics share dividends
We're not expecting Cara Therapeutics to pay a dividend over the next 12 months.
Have Cara Therapeutics's shares ever split?
Cara Therapeutics's shares were split on a 1:2 basis on 15 January 2014. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cara Therapeutics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Cara Therapeutics shares which in turn could have impacted Cara Therapeutics's share price.
Cara Therapeutics share price volatility
Over the last 12 months, Cara Therapeutics's shares have ranged in value from as little as US$11.22 up to US$29.6473. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cara Therapeutics's is 1.0284. This would suggest that Cara Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cara Therapeutics overview
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Cara Therapeutics in the news
CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Frequently asked questions
More guides on Finder
How to watch Sydney Sixers vs Sydney Thunder BBL live and match preview
The Sixers and Thunder clash in the biggest Sydney Derby in the history of the Big Bash League.
Where to watch Harry Potter: Hogwarts Tournament of Houses online
Who will be declared House Cup Champion?
How to watch Ray Donovan: The Movie online in Australia
Will Mickey Donovan finally die in this wrap-up movie?
RAT scams: How to avoid getting conned with rapid antigen tests
Don't fall for the scam artists when you're trying to protect your health - here's what to check.
How to do a COVID-19 test at home for international travel
Here's where you can book COVID-19 at-home tests approved for travel and how they work.
Where to shop every product in Kiernan Shipka’s beauty routine
We've rounded up everything you need to nail the 'date-worthy' makeup look, including some affordable dupes.
American Express Corporate Gold Card
Designed for big companies, this Amex charge card offers a mix of management tools and perks – including a 100,000 bonus Membership Rewards offer.
Rapid antigen tests: When will RAT stock be available? [UPDATED]
Rapid antigen tests are proving extremely hard to find, but there are options if you can be patient trying to find a RAT.
Beauty Product of the Week: Milk Makeup Hydro Grip Primer
We tried the viral Milk Makeup Hydro Grip Primer and spoiler alert, it's the bee's knees.
Where to watch Hotel Transylvania 4 online for free in Australia
Drac and the Pack are back, like you’ve never seen them before.
Ask an Expert